As inhaled therapeutics, nucleic acid-based medicines, nanomedicine, exosome therapies, and biologics continue to gain momentum, the importance of preclinical inhalation studies is rapidly increasing. However, current animal inhalation research workflows still face several key challenges, including invasive tracheal administration procedures, uncertainty in actual inhalation pathways within chamber-based exposure systems, and difficulty in accurately estimating inhaled doses. These limitations can affect study reproducibility, data reliability, and operational efficiency.

AeproMED, a company with extensive expertise in aerosol science and inhalation technology development, has announced the launch of AniFree™, an inhalation delivery platform specifically designed for preclinical animal studies. Integrating aerosol engineering, airflow design, and intelligent control technologies, AniFree™ aims to provide a more precise, safer, and research-oriented solution for inhalation drug delivery.

Unlike traditional tracheal administration approaches that often require complex surgical procedures, AniFree™ features a specially designed airflow pathway that enables experimental animals to receive aerosols through natural nose-to-mouth inhalation. This approach minimizes the need for invasive procedures, reduces physiological stress on animals, lowers operational complexity, and supports improved experimental consistency and efficiency.

Conventional chamber-based inhalation exposure systems may also present challenges in distinguishing true inhalation exposure from unintended exposure routes, such as deposition on fur, skin, or other non-target pathways. AniFree™ addresses this issue with a focused inhalation airflow design that directs aerosol delivery specifically toward the animal’s nose and mouth region, helping researchers establish more controlled inhalation conditions and improve confidence in exposure and data interpretation.

To further support dose optimization, AniFree™ can be integrated with customized nebulization parameters, including aerosol particle size, output performance, and formulation-specific settings. This flexibility allows researchers to optimize inhalation conditions according to different therapeutic modalities and animal models, potentially improving delivery efficiency and enhancing study reproducibility.

AniFree™ also incorporates remote app-based control and monitoring capabilities, enabling researchers to operate the system at a distance. This feature helps reduce personnel exposure risk while improving workflow convenience and laboratory safety.

According to AeproMED, the development of AniFree™ was driven by the goal of addressing three major challenges in preclinical inhalation research: complex procedures, uncertain exposure pathways, and difficult dose control. The company believes the platform can support a broad range of research areas, including inhaled therapeutics, respiratory disease treatment, vaccines, biologics, and regenerative medicine applications.

Looking ahead, AeproMED plans to continue expanding its AIRHYPER™ Platform technologies by further enhancing aerosol particle control, airflow simulation, and precision drug delivery capabilities. The company aims to build a comprehensive inhalation ecosystem spanning from preclinical research to future clinical applications and contribute to the next generation of smart inhalation healthcare solutions.